Table 2.
Primary perinatal and maternal outcomes comparing oral magnesium citrate vs. placebo
| Outcome |
Magnesium citrate (n = 407) |
Placebo (n = 422) |
Unadjusted relative risk (95% confidence interval) |
Adjusted odds ratioa (95% confidence interval) |
|---|---|---|---|---|
| Primary perinatal composite outcome | 75 (18.4) | 76 (18.0) | 1.02 (0.76 to 1.36) | 1.10 (0.72 to 1.68) |
| Preterm birth < 37 weeks’ gestation | 38 (9.3) | 38 (9.0) | 1.04 (0.68 to 1.59) | 1.02 (0.64 to 1.65) |
| Stillbirth > 20 weeks’ gestation | 0 (0.0) | 1 (0.2) | Not calculable | Not calculable |
| Neonatal death < 28 days after birth | 4 (0.9) | 10 (2.3) | 0.41 (0.13 to 1.31) | 0.39 (0.12 to 1.27) |
| NICU admission < 28 days after birth | 12 (2.9) | 9 (2.1) | 1.38 (0.58 to 3.24) | 1.38 (0.59 to 3.21) |
| Small for gestational age birthweight < 3rd percentile | 21 (5.1) | 18 (4.2) | 1.21 (0.65 to 2.24) | 1.37 (0.71 to 2.66) |
| Primary maternal composite outcome | 49 (12.0) | 41 (9.7) | 1.24 (0.84 to 1.83) | 1.29 (0.83 to 2.00) |
| Preeclampsia < 37 weeks’ gestation | 24 (5.9) | 20 (4.7) | 1.24 (0.70 to 2.22) | 1.25 (0.68 to 2.31) |
| Severe gestational hypertension < 37 weeks’ gestation | 20 (4.9) | 19 (4.5) | 1.09 (0.59 to 2.01) | 1.18 (0.62 to 2.26) |
| Placental abruption | 9 (2.2) | 21 (5.0) | 0.44 (0.21 to 0.96) | 0.43 (0.20 to 0.95) |
| Maternal stroke during pregnancy or ≤ 7 days after birth | 0 (0.0) | 0 (0.0) | Not calculable | Not calculable |
| Maternal death during pregnancy or ≤ 7 days after birth | 1 (0.2) | 0 (0.0) | Not calculable | Not calculable |
aOdds ratios were adjusted for gestational age at trial entry and cohabitation with a partner, using logistic regression analysis